Brent Standridge
2016
In 2016, Brent Standridge earned a total compensation of $1.1M as Chief Operating Officer at Aratana Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $49,200 |
|---|---|
| Option Awards | $362,285 |
| Salary | $150,000 |
| Stock Awards | $348,919 |
| Other | $140,204 |
| Total | $1,050,608 |
Standridge received $362.3K in option awards, accounting for 34% of the total pay in 2016.
Standridge also received $49.2K in non-equity incentive plan, $150K in salary, $348.9K in stock awards and $140.2K in other compensation.
Rankings
In 2016, Brent Standridge's compensation ranked 8,002nd out of 14,075 executives tracked by ExecPay. In other words, Standridge earned more than 43.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,002 out of 14,075 | 43rd |
Division Manufacturing | 3,051 out of 5,489 | 44th |
Major group Chemicals And Allied Products | 1,013 out of 1,895 | 47th |
Industry group Drugs | 783 out of 1,538 | 49th |
Industry Pharmaceutical Preparations | 621 out of 1,176 | 47th |
Source: SEC filing on June 8, 2018.
Standridge's colleagues
We found three more compensation records of executives who worked with Brent Standridge at Aratana Therapeutics in 2016.